Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Net Cash Flow (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Net Cash Flow for 16 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 121.8% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 311.82% increase, with the full-year FY2024 number at $447000.0, up 103.06% from a year prior.
  • Net Cash Flow was $3.5 million for Q3 2025 at Xtant Medical Holdings, up from $1.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $16.3 million in Q1 2021 to a low of -$15.1 million in Q1 2023.
  • A 5-year average of $440105.3 and a median of -$124000.0 in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 1379.3% in 2022, then plummeted 966.17% in 2023.
  • Xtant Medical Holdings' Net Cash Flow stood at -$227000.0 in 2021, then soared by 1379.3% to $2.9 million in 2022, then tumbled by 199.97% to -$2.9 million in 2023, then surged by 73.96% to -$756000.0 in 2024, then soared by 565.61% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Net Cash Flow are $3.5 million (Q3 2025), $1.6 million (Q2 2025), and -$784000.0 (Q1 2025).